Fenebrutinib clinical trials
Fenebrutinib is named as an intervention in 5 current clinical trials in our USA, Poland, Mexico, Spain, Italy, Portugal, Brazil, UK, Germany, France, Denmark, Switzerland, Austria, Turkey, Canada, Australia, Israel, India, South Korea, Czechia, China and Netherlands registers. 1 is recruiting patients now. The most common phase is Phase 3. The lead sponsor is Hoffmann-La Roche. The most-studied condition is Relapsing Multiple Sclerosis.
How Fenebrutinib works
All drug targets →- Tyrosine-protein kinase BTK inhibitor InhibitorTarget: BTK Bruton tyrosine kinase✓ In ChEMBL and the Guide to Pharmacology
- Multiple sclerosis symptom measurementPhase 3
- Chronic idiopathic urticariaPhase 2
- Rheumatoid arthritisPhase 2
- Systemic lupus erythematosusPhase 2
- B-cell chronic lymphocytic leukemiaPhase 1
- Autoimmune diseasePhase 1
- Non-Hodgkin lymphomaPhase 1
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL4065122, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 9299, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Fenebrutinib
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Fenebrutinib
5 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Fenebrutinib
2 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Hoffmann-La Roche | 5 |
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Fenebrutinib trials
How many clinical trials are testing Fenebrutinib?
5 current trials in our USA, Poland, Mexico, Spain, Italy, Portugal, Brazil, UK, Germany, France, Denmark, Switzerland, Austria, Turkey, Canada, Australia, Israel, India, South Korea, Czechia, China and Netherlands registers name Fenebrutinib as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Fenebrutinib trials recruiting patients?
Yes. 1 of the 5 trials is recruiting: 1 with sites in Poland, 1 with sites in Mexico, 1 with sites in Spain, 1 with sites in Portugal and 1 with sites in Brazil. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Fenebrutinib clinical trials?
The lead sponsor is Hoffmann-La Roche. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Fenebrutinib works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Fenebrutinib works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Fenebrutinib (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.